GRAL
GRAIL, Inc.NASDAQHealthcare$54.99-5.91%ClosedMarket Cap: $2.26B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.82
P/S
14.42
EV/EBITDA
-5.31
DCF Value
$-19.24
FCF Yield
-14.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-42.5%
Operating Margin
-382.0%
Net Margin
-277.5%
ROE
-17.1%
ROA
-14.0%
ROIC
-15.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $43.6M | -25.5% | $-124.4M | $-99.2M | $-2.44 | — |
| FY 2025 | $147.2M | -42.5% | $-534.2M | $-408.4M | $-11.11 | — |
| Q3 2025 | $36.2M | -37.9% | $-125.3M | $-89.0M | $-2.46 | — |
| Q2 2025 | $35.5M | -50.0% | $-158.9M | $-114.0M | $-3.18 | — |
| Q1 2025 | $31.8M | -62.6% | $-153.6M | $-106.2M | $-3.10 | — |
| Q4 2024 | $38.3M | -41.7% | $-136.9M | $-97.1M | $-2.89 | — |
| FY 2024 | $125.6M | -62.1% | $-2.19B | $-2.03B | $-63.54 | — |
| Q3 2024 | $28.7M | -77.6% | $-183.5M | $-125.7M | $-3.94 | — |
| Q2 2024 | $32.0M | -56.0% | $-1.64B | $-1.59B | $-51.06 | — |
| Q1 2024 | $26.7M | -82.0% | $-227.4M | $-218.9M | $-7.05 | — |
| Q4 2023 | $30.3M | -61.5% | $-194.6M | $-5.5M | $-0.18 | — |
| FY 2023 | $93.1M | -102.7% | $-1.52B | $-1.47B | $-47.20 | — |